Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

European Electrotechnics reported for 9 months of 2023 by RAS

11/2/23 EELT

Shell announced a quarterly dividend

11/2/23 SHEL

Shell reported for 9 months of 2023

11/2/23 SHEL

Sberbank reported for 9 months of 2023 by IFRS

11/2/23 SBER

Henderson set the IPO price at an upper bound of ₽675

11/2/23 HNFG

TCS Group claims forced redomiciliation

11/2/23 T

Yango has launched its own navigation service in Dubai

11/2/23 YNDX

Court invalidated the sale of Zdorovaya Farma to Cherkizovo Group

11/2/23 GCHE

Mondelēz International reported for 9 months of 2023

11/2/23 MDLZ

PayPal reported for 9 months of 2023

11/2/23 PYPL